CN102872103A - Application of Houttuynoid E in medicine for treating nasopharyngeal carcinoma - Google Patents
Application of Houttuynoid E in medicine for treating nasopharyngeal carcinoma Download PDFInfo
- Publication number
- CN102872103A CN102872103A CN2012104191066A CN201210419106A CN102872103A CN 102872103 A CN102872103 A CN 102872103A CN 2012104191066 A CN2012104191066 A CN 2012104191066A CN 201210419106 A CN201210419106 A CN 201210419106A CN 102872103 A CN102872103 A CN 102872103A
- Authority
- CN
- China
- Prior art keywords
- houttuynoid
- nasopharyngeal carcinoma
- medicine
- application
- preparing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The invention discloses application of Houttuynoid E in preparing a medicine for treating nasopharyngeal carcinoma, belonging to the technical field of new application of a medicine. According to the invention, the in-vitro MTT anti-tumor activity evaluation discovers that the Houttuynoid E also has an obvious effect on suppressing the growth of human nasopharyngeal carcinoma cell strains HNE1, HNE2, HONE1 and CNE1. Thus, the Houttuynoid E can be used for preparing an anti-nasopharyngeal carcinoma medicine and has good prospects in development and application. The application of Houttuynoid E in preparing a medicine for treating nasopharyngeal carcinoma is disclosed for the first time; and the skeleton type is a brand new one, and the activity in suppressing nasopharyngeal carcinoma cells is unexpectedly strong.
Description
Technical field
The present invention relates to the new purposes of compound H outtuynoid E, relate in particular to the application of Houttuynoid E in the anti-medicine for nasopharyngeal of preparation.
Technical background
Cancer is to one of disease of human life's health hazard maximum, and annual have a large amount of people to die from cancer.The research and development of cancer therapy drug are the focuses of study of pharmacy always.Having 74% to be the natural product or derivatives thereof in the antitumor drug, is exactly the present reasonable antitumor drug of effect clinically such as paclitaxel and derivant thereof.Therefore, searching anticancer compound or lead compound have great importance from natural product.
The compound H outtuynoid E that the present invention relates to is one and delivered (Chen in 2012, S. D. et al., 2012. Houttuynoid E_E, Anti-Herpes Simplex Virus Active Flavonoids with Novel Skeletons from Houttuynia cordata. Organic Letters 14 (7), 1772 – 1775.) New skeleton compound, this chemical compound has brand-new framework types, present purposes only relates to anti-herpes simplex virus activity (Chen, S. D. et al., 2012. Houttuynoid E_E, Anti-Herpes Simplex Virus Active Flavonoids with Novel Skeletons from Houttuynia cordata. Organic Letters 14 (7), 1772 – 1775.), belong to open first for the purposes of the Houttuynoid E that the present invention relates in preparation treatment medicine for nasopharyngeal, because framework types belongs to brand-new framework types, and its inhibition for nasopharyngeal carcinoma cell is active unexpectedly strong, there is not the possibility that is provided any enlightenment by other chemical compounds, possess outstanding substantive distinguishing features, the control that is used for simultaneously nasopharyngeal carcinoma obviously has significant progress.
Summary of the invention
The invention provides the application of compound H outtuynoid E in the preparation antitumor drug.
The present invention adopts following technical scheme: the application of Houttuynoid E in the anti-medicine for nasopharyngeal of preparation, and the structural formula of Houttuynoid E is shown in formula I:
The present invention finds that by external MTT anti-tumor activity evaluation Houttuynoid E also has significant inhibitory action to the growth of human nasopharyngeal carcinoma cell line HNE1, HNE2, HONE1 and CNE1, suppresses the IC of this 4 strain Growth of Cells
50Value is respectively 0.11 ± 0.02 μ M, 0.49 ± 0.29 μ M, 1.03 ± 0.21 μ M and 1.41 ± 0.44 μ M.Therefore, Houttuynoid E can for the preparation of anti-medicine for nasopharyngeal, have good development prospect.
Belong to open first for the purposes of the Houttuynoid E that the present invention relates in preparation treatment medicine for nasopharyngeal, because framework types belongs to brand-new framework types, and its inhibition for nasopharyngeal carcinoma cell is active unexpectedly strong, there is not the possibility that is provided any enlightenment by other chemical compounds, possess outstanding substantive distinguishing features, the control that is used for simultaneously nasopharyngeal carcinoma obviously has significant progress.
The present invention is further detailed explanation by the following examples, but protection scope of the present invention is not subjected to any restriction of specific embodiment, but limited by claim.
The specific embodiment
The preparation method of compound H outtuynoid E involved in the present invention is referring to document (Chen, S. D. et al., 2012. Houttuynoid E_E, Anti-Herpes Simplex Virus Active Flavonoids with Novel Skeletons from Houttuynia cordata. Organic Letters 14 (7), 1772 – 1775.).
The present invention is further detailed explanation by the following examples, but protection scope of the present invention is not subjected to any restriction of specific embodiment, but limited by claim.
Embodiment 1: the preparation of compound H outtuynoid E tablet involved in the present invention:
Get 20 and digest compound Houttuynoid E, add conventional adjuvant 180 grams of preparation tablet, mixing, conventional tablet machine are made 1000.
Embodiment 2: the preparation of compound H outtuynoid E capsule involved in the present invention:
Get 20 and digest compound Houttuynoid E, add conventional adjuvant such as starch 180 grams of preparation capsule, mixing is encapsulatedly made 1000.
Further specify its pharmaceutically active below by pharmacodynamic experiment.
Experimental example: adopt mtt assay assessing compound Houttuynoid E to the growth inhibited effect of human nasopharyngeal carcinoma cell line
1. method: the cell that is in the growth logarithmic (log) phase: human nasopharyngeal carcinoma cell line HNE1, HNE2, HONE1 and CNE1(buy from Chinese Academy of Sciences's cell bank) with 1.5 * 10
4The concentration kind is in 96 orifice plates.Suck original culture medium after cell culture 24 h are adherent.Test is divided into blank group, drug treating group.Blank group is changed 1640 culture medium that contain 10% hyclone; It is 100 μ M that the replacing of drug treating group contains concentration, 50 μ M, 10 μ M, 1 μ M, 0.1 μ M, the culture medium of the Houttuynoid E of 0.01 μ M and 0.001 μ M.After cultivating 48 h, add the MTT of concentration 5mg/mL, continue to be put in CO
2Incubator is cultivated 4 h, then suck 100 μ L supernatants along culture fluid top, add 100 μ L DMSO, 10 min are placed in the dark place, utilize microplate reader (Sunrise company product) to measure light absorption value (wavelength 570nm), and according to light absorption value calculating cell survival situation, 6 repeating holes are established in each processing.Cell survival rate (%)=Δ OD
Drug treating/ Δ OD
Blank* 100.
2. result: Houttuynoid E has significant inhibitory action to the growth of human nasopharyngeal carcinoma cell line HNE1, HNE2, HONE1 and CNE1.This chemical compound suppresses the IC of human nasopharyngeal carcinoma cell line HNE1, HNE2, HONE1 and CNE1 growth
50Value is respectively: 0.11 ± 0.02 μ M, 0.49 ± 0.29 μ M, 1.03 ± 0.21 μ M and 1.41 ± 0.44 μ M.
Shown that by above-described embodiment Houttuynoid E of the present invention has good inhibitory action to the growth of human nasopharyngeal carcinoma cell line HNE1, HNE2, HONE1 and CNE1.Prove that thus it is active that Houttuynoid E of the present invention has anti-nasopharyngeal carcinoma, can be for the preparation of anti-medicine for nasopharyngeal.
Claims (1)
1.Houttuynoid E is in the application for the treatment of in the medicine for nasopharyngeal, described compound H outtuynoid E structure as
Formula IShown in:
Formula I.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210419106.6A CN102872103B (en) | 2012-10-27 | 2012-10-27 | The application of Houttuynoid E in treatment medicine for nasopharyngeal |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210419106.6A CN102872103B (en) | 2012-10-27 | 2012-10-27 | The application of Houttuynoid E in treatment medicine for nasopharyngeal |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102872103A true CN102872103A (en) | 2013-01-16 |
| CN102872103B CN102872103B (en) | 2015-08-19 |
Family
ID=47473774
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201210419106.6A Expired - Fee Related CN102872103B (en) | 2012-10-27 | 2012-10-27 | The application of Houttuynoid E in treatment medicine for nasopharyngeal |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102872103B (en) |
-
2012
- 2012-10-27 CN CN201210419106.6A patent/CN102872103B/en not_active Expired - Fee Related
Non-Patent Citations (2)
| Title |
|---|
| CHEN，S.D. ET AL: "Houttuynoid A-E, Anti-Herpes Simplex Virus Active Flavonoids with Novel Skeletons from Houttuynia cordata", 《ORGANIC LETTERS》 * |
| 闫双银: "鱼腥草的研究进展", 《海峡药学》 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102872103B (en) | 2015-08-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102872095B (en) | Application of Houttuynoid E in medicine for treating ileocecum cancer | |
| CN102872101B (en) | Application of Houttuynoid C in medicine for treating ileocecum cancer | |
| CN102872134B (en) | Application of Houttuynoid D in drug for treating laryngocarcinoma | |
| CN102872109B (en) | Application of Houttuynoid A in medicament for treating prostate cancer | |
| CN102861084B (en) | Application of Houttuynoid D in medicine for treating ileocecum cancer | |
| CN102872076B (en) | Application of Houttuynoid A in drugs for treating tongue cancer | |
| CN102861099A (en) | Application of Houttuynoid D in medicine for treating endometrial cancer | |
| CN102861080B (en) | Application of Houttuynoid C in medicine for treating nasopharynx cancer | |
| CN102861073A (en) | Application of Houttuynoid A in medicine for treating colorectal cancer | |
| CN102872112B (en) | Application of Houttuynoid A in medicament for treating bladder cancer | |
| CN102861065A (en) | Application of Houttuynoid E in medicine for treating gastric cancer | |
| CN102872103A (en) | Application of Houttuynoid E in medicine for treating nasopharyngeal carcinoma | |
| CN102861048A (en) | Application of Houttuynoid A in medicine for treating nasopharyngeal carcinoma | |
| CN102861070A (en) | Application of Houttuynoid E in medicine for treating tongue cancer | |
| CN102861074A (en) | Application of Houttuynoid B in medicine for treating bladder cancer | |
| CN102861064A (en) | Application of Houttuynoid E in medicine for treating laryngocarcinoma | |
| CN102861069A (en) | Application of Houttuynoid B in medicine for treating laryngocarcinoma | |
| CN102872144A (en) | Application of Houttuynoid D in drug for treating bladder cancer | |
| CN102872092A (en) | Application of Houttuynoid E in medicine for treating kidney cancer | |
| CN102861093A (en) | Application of Houttuynoid B in medicine for treating colorectal cancer | |
| CN102861097A (en) | Application of Houttuynoid E in medicine for treating bladder cancer | |
| CN102872135A (en) | Application of Houttuynoid D in drug for treating renal cancer | |
| CN102872139A (en) | Application of Houttuynoid C in drug for treating tongue cancer | |
| CN102861078A (en) | Application of Houttuynoid D in medicine for treating prostatic cancer | |
| CN102861086A (en) | Application of Houttuynoid E in medicine for treating ovarian cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20150819 Termination date: 20151027 |
|
| EXPY | Termination of patent right or utility model |